MedPath

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Phase 4
Conditions
Osteoporotic Pain
Interventions
Registration Number
NCT04524169
Lead Sponsor
RenJi Hospital
Brief Summary

Osteoporotic pain is the most common clinical symptom in elderly patients. The course of pain is prolonged and the effect of clinical treatment is limited. This study will observe the therapeutic effect of thymosin alpha 1 on elderly patient with osteoporotic pain and explore its immunotherapy mechanism.

Detailed Description

About 70% of the elderly patients suffered osteoporotic pain, mainly involving the limbs and low back. The pain prolonged and varies from mild to severe, and the effect of the clinical treatment is poor which has become a serious social problem. Recent studies have put forward a new point of "bone Immunology", which suggests that immune system, especially CD4+ T cell system, are involved in the regulation of bone formation, bone resorption and bone remodeling. So, in this study, the investigators will observe the therapeutic effect of thymosin alpha 1 on osteoporotic pain in elderly by observing the improvement of VAS score before and after the treatment, as well as the changes of proportion of peripheral blood CD4+ T lymphocyte subsets, bone mineral density, serum bone biochemical index, neuropeptides, RANKL and other cytokines levels will be evaluated. The clinical safety of thymosin alpha 1 in elderly patients with osteoporotic pain will also be observed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients suffered osteoporotic pain diagnosed by specialists
  • VAS scores greater than 5
  • Normal reading and understanding ability
  • Communicate normally
  • Volunteer to participate
Exclusion Criteria
  • Mental illness
  • Serious physical disease
  • Unwilling to cooperate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Thymosin Alpha 1Thymosin Alpha1Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Primary Outcome Measures
NameTimeMethod
Change of VAS scores4 week

The VAS (visual analogue scale) is a scale used to determine the pain intensity experienced by individuals. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain", "0" means no pain, "10" means severe worst pain. In our study VAS score will be record before and after 4 weeks of treatment.

Secondary Outcome Measures
NameTimeMethod
Change of BMD value4 week

A bone mineral density (BMD) test is an easy, reliable test that measures the thickness of the bones and the response to osteoporosis treatment. We perform the BMD test by X-rays and record participants' BMD values before and after 4 weeks of treatment.

Trial Locations

Locations (1)

Diansan Su

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath